对于用于产生抗体-药物联合体的药物链接剂相关杂质的杂质合格要求
Osama Chahrour1, Paul D Cornwell2, Penny Leavitt3
1Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK.
Regulatory toxicology and pharmacology : RTP
|October 25, 2025
概括
抗体 - 药物合物 (ADC) 的药物链接剂 (D-L) 中间体中的有机杂质在1.0%以下的重量中构成最小的毒理风险. 这项研究建议将DL杂质的合格限值提高到1.0%w/w,从而加强ADC的安全评估.
科学领域:
- 制药化学 制药化学 制药化学
- 毒理学 毒理学 毒理学
- 药物开发 药物开发
背景情况:
- 抗体-药物结合物 (ADC) 在瘤学中至关重要.
- 药物链接剂 (D-Ls) 是ADC生产中的关键中间体.
- 评估D-Ls中的有机杂质的毒理风险对于ADC安全至关重要.
研究的目的:
- 对DL中间体中的有机杂质进行基于科学的毒理风险评估.
- 建议对ADC制造中的D-L相关杂质提出修订后的合格限值.
- 引入一种方法来评估D-Ls中不可结合的有机杂质.
主要方法:
- 对D-L中间产品中有机杂质的整体毒理学评估.
- 分析杂质含量及其对ADC药物最终产品的潜在影响.
- 开发基于风险的方法来证明杂质规范的合理性.
主要成果:
- 在D-L中间体中,有机杂质在1.0%或以下的重量不太可能引起有害的毒理影响.
- 提议将D-L相关杂质的合格限值从0.15%提高到1.0%w/w.
- 基于工艺和ADC特定因素评估不可结合杂质的方法.
结论:
- 目前D-L杂质的毒理风险在高达1.0%重/重的水平是最小的.
- 修订的资格限制和风险评估策略可以确保ADC的安全性和质量.
- 建议制定D-L杂质质量风险管理工作流程,以支持ADC的开发.
相关概念视频
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
148
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
148
Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
Immunoprecipitation
6.7K
Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
6.7K
Affinity Chromatography
2.7K
Affinity chromatography is a powerful technique extensively utilized for separating and purifying specific biomolecules from complex mixtures. It capitalizes on the highly selective binding between an analyte and its counterpart, such as antibody-antigen interactions. The counterpart is immobilized on the stationary phase, forming an affinity column. The stationary phase typically consists of solid support, such as agarose or porous glass beads, immobilizing the affinity ligand. The mobile...
2.7K
Phase II Conjugation Reactions: Overview
719
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
719


